在耐药性患者的迷你神经刺激疗法期间,响应抑制,视觉预测和口头流利性的变化
Niina Lähde1,2, Pabitra Basnyat2, Jani Raitanen3,4
1Department of Neurology, Tampere University Hospital, Tampere, Finland.
Brain and behavior
|December 6, 2024
概括
神经刺激 (VNS) 疗法在5年内显著改善了耐药患者的迷宫表现. 虽然其他认知功能保持稳定,但VNS疗法在特定患者群体的注意力和执行功能方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 的研究研究.
- 认知功能 认知功能
背景情况:
- 神经刺激 (VNS) 是一种治疗耐药性的方法.
- 在DRE患者中,VNS对注意力和执行功能 (AEF) 的影响需要进一步研究.
- 这项研究检查了接受VNS治疗的DRE患者的认知表现变化.
研究的目的:
- 研究VNS对认知领域的长期影响,特别是注意力和执行功能 (AEF).
- 分析在多达五年的随访期内接受VNS治疗的DRE患者的认知测试中评估AEF的性能变化.
主要方法:
- 33名DRE患者使用干扰,迷宫和书面口语流性测试进行了评估.
- 在VNS植入之前和之后进行认知评估,并进行了反复的随访.
- 采用线性混合效应模型来分析随时间变化的测试成绩.
主要成果:
- 迷宫测试的性能显著改善,平均每月0.20秒.
- 干扰测试的表现和口语流性显示出非显著的改善趋势.
- 患有精神病并发症,额叶或服用1-2种抗发作药物 (ASM) 的患者在特定的认知任务中表现出最显著的改善.
结论:
- 视觉神经系统治疗导致迷宫表现显著改善,表明视觉预测和规划得到了增强.
- 响应抑制等认知功能在群体水平上保持稳定,尽管在特定子组中注意到了改善.
- 精神病并发症与迷宫表现的更大改善有关,这表明潜在的调节效应.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
248
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
248
Antiepileptic Drugs: Potassium Channel Activators
144
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
144


